Every year, the American Society of Retina Specialists releases the results of its latest Preferences and Trends Survey at the annual meeting. This year, the survey highlighted some surprising differences between US and international retina specialists, including off-label medication use and what drives drug choices for patients, said Paul Hahn, MD, vitreoretinal surgeon at NJRetina.
Every year, the American Society of Retina Specialists releases the results of its latest Preferences and Trends Survey at the annual meeting. This year, the survey highlighted some surprising differences between US and international retina specialists, including off-label medication use and what drives drug choices for patients, said Paul Hahn, MD, vitreoretinal surgeon at NJRetina.
Transcript
Have there been any major surprises with the results of the American Society of Retina Specialists' Preferences and Trends Survey in recent years?
So the Preferences and Trends Survey is really designed to capture the preferences and trends of retina specialists year over year. And I think for the most part, we have a pretty good handle on the pulse of retina specialists. So, I can't say there have been any major surprises. There are a couple of things that are of interest, though, or perhaps are surprising.
For example, if we compare US versus international retina specialists’ responses, we'll see that the majority of US retina specialists use an off-label medication for treatment of retinal diseases as first line, whereas international retina specialists, at least surprising to me, tend to use less of that off-label medication. It's surprising because in the US, we do have FDA-approved options that are very effective,, if not more effective for those retinal diseases. The etiology for this is unclear. The reason for this is unclear. I would personally suspect that this reflects differences in health care systems.
So, in the US this year, our survey asked a separate question, which was the No. 1 reason why retina specialists choose the drugs that they choose, and 25% of responding retina specialists reported that the most important factor in selecting drugs were insurance mandates, beating out, for example, efficacy and safety, which at least to me, should be No. 1. Internationally, that number was only 12%. So again, this probably reflects differences in health care delivery systems, probably accounting for that disparity.
Another surprising response was that in the US, we saw a lot of retina specialists reporting difficulty in hiring staff—not surprising in itself. There's been a pervasive labor shortage, probably across all markets over the past year or so. But surprisingly, internationally, we didn't see that same difficulty. And I'm not sure if there's a selection bias or what the reason for that is, but another interesting difference.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More